A double blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c administrations of 100µg NIC002 vaccine in cigarette smokers who are motivated to quit smoking

Woman and Man

| Country :
| organs :
| Specialty :

Extract

To test the hypothesis that treatment with NIC002 increases the 4-week rate of continuous abstinence from smoking between weeks 8 and 12 inclusive compared with placebo

Inclusion criteria

smokers

Kusajili – Clinical trials directory

A double blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c administrations of 100µg NIC002 vaccine in cigarette smokers wh...

A double blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c administrations of 100µg NIC002 vaccine in cigarette smokers who are motivated to quit smoking

Woman and Man

Extract

Inclusion criteria

Links